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| Summary |
Dengue is an infection caused by dengue virus and is the most 
important arthropod transmitted viral disease in the world, 
causing near 100 million cases and 50 000 fatalities each year. 
Health authorities believe that these numbers will grow in 
coming years. In Colombia, almost 600 municipalities are in 
regions with Aedes aegypti circulation, and the presence of four 
dengue serotypes has been demonstrated. Despite the increasing 
knowledge about disease pathogenesis and the dengue virus, 
some technical or scientific difficulties with diagnosing dengue 
remain, negatively affecting both public health surveillance 
and the appropriate attention to patients in health settings and 
hospitals. This paper reviews the principles and developments 
of the current diagnostic techniques for dengue, pointing out 
the difficulties with making accurate dengue diagnoses and case 
confirmations in public health and specialized laboratories. The 
principles and limitations of MAC-ELISA, IgG serology, viral 
NS1 detection and viral isolation by cell culture are presented. 
In addition, the review of immunochromatography techniques 
(rapid diagnostic tests) that have been put forward to help the 
point-of-care diagnosis is proposed. This paper is intended to 
bring forward some points of view about the issues related to 
dengue diagnosis and contribute to improve the discussion 
surrounding the strategies and techniques needed for reducing 
the impact of the disease and favoring its control. 
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Resumen
La infección por el virus de dengue es la enfermedad viral 
transmitida por insectos más importante del mundo que 
genera grandes gastos a los sistemas de salud. En Colombia, 
en más de 600 municipios está presente el mosquito vector 
y se ha detectado la circulación de los cuatro serotipos del 
virus, haciendo previsible que la incidencia y prevalencia 
sigan aumentando. Aunque se han hecho grandes avances 
y desarrollos para entender la enfermedad, existen vacíos 
científicos y técnicos que dificultan su correcto diagnóstico 
y que debilitan tanto la vigilancia en salud pública como la 
correcta atención en las instituciones prestadoras de salud. En 
este documento se revisan los principios e interpretaciones de 
las herramientas de laboratorio disponibles para el diagnóstico 
de dengue, haciendo énfasis en las dificultades existentes para 
la correcta definición de los casos desde el laboratorio general 
y especializado. Se explican los fundamentos y limitaciones de 
las técnicas de ELISA de captura de anticuerpos IgM, serología 
para IgG, detección del antígeno viral NS1, aislamiento viral 
en cultivos celulares y las pruebas más recientes basadas en 
la inmunocromatografía –pruebas rápidas–. La revisión se 
propone, además de aportar a la discusión sobre las dificultades 
para el diagnóstico en dengue, ofrecer una idea actualizada sobre 
cómo abordar el diagnóstico tanto en los laboratorios de salud 
pública como en los laboratorios especializados y contribuir así 
a mejorar los estándares de atención de los pacientes, reducir el 
impacto de la enfermedad y favorecer su control.  
Palabras clave: Dengue; Diagnóstico; Flavivirus; Serología; 
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Introduction
The dengue virus, whose official acronym is DENV, is a 
small virus that contains a genome of positive-sense RNA. 
It is responsible for the most important infectious disease 
transmitted by mosquitoes in the world. This disease is 
widely distributed through more than 100 countries, mostly in 
tropical and sub-tropical zones (1). More than a million cases 
of dengue are reported around the world each year, and the 
number of deaths may be approximately 50000 (2). Dengue 
infection has a wide spectrum of clinical manifestations 
that go from infections without symptoms to fatal cases. 
According to the new classification from the World Health 
Organization (WHO), in cases where symptoms appear, they 
can present as an undifferentiated febrile illness (dengue), 
or as a severe disease (severe dengue), characterized by 
plasmatic extravasations, hemorrhages, and, in some cases, 
compromising of organs like the brain, liver, or heart (3,4). 
Patients with dengue consult health institutions motivated 
by symptoms of high fever, headache, retrobulbar pain, 
arthralgia, chills, and, in some cases, rash. These signs 
and symptoms define a probable clinical presentation of 
dengue. If, in addition, the patient presents some additional 
sign like abdominal pain, vomiting, edema, bleeding of the 
mucous membranes, hepatomegaly, or thrombocytopenia, the 
presentation is denominated “dengue with warning signs”. 
A clinical presentation of “severe dengue” is diagnosed 
if, in addition to the previous signs, there is evidence of 
plasma leakage (pleural effusion, ascites, shock), or severe 
hemorrhages, or severe damage in an organ (for example 
the liver, the nervous system, the heart, the kidneys). In all 
of these cases, the support of both general and specialized 
laboratories is required so that the event goes from “probable 
case” to “confirmed case” (5). Although, normally, severe 
disease in children is considered to have the worst prognosis, 
indicators of severity like vomit, abdominal pain, bleeding 
of the mucous membranes were significantly more frequent 
in adults than in children according to a recent study from a 
cohort in Vietnam (6) 
National and international organisms consider disease 
due to dengue to be an event of interest for public health 
and notifying the appropriate authorities is obligatory (7). 
In Colombia, the Ministry of Health, through the National 
Health Institute (INS, Instituto Nacional de Salud), carries 
out surveillance following the guidelines of the PAHO/WHO 
with the goal of studying the areas in which cases occur 
and of proposing activities for controlling the disease when 
outbreaks or epidemics appear. The laboratories of clinics and 
hospitals fulfill an important role in this task, performing IgM 
antibody detection tests in blood serum samples of probable 
cases and the results are sent to the Regional Laboratories 
of Public Health, who confirm a percentage of the samples 
and consolidate the information that they should report to 
the national surveillance system. Some of these samples are 
sent to the Virology Laboratory of the INS for virological 
surveillance, viral isolation, or the detection of viral RNA 
through RT-PCR. 
The role of health personnel in the management of the cases 
and breakouts is more and more important, especially in the 
detection of cases, their evaluation, and patient follow-up, 
as well as in the respective notification of the surveillance 
systems. Several studies have been performed in which 
the different signs, symptoms and data obtained in clinical 
laboratory tests are evaluated as elements that can be used for 
making earlier and acurate diagnoses (8-10). Nonetheless, it 
is clear that the clinical diagnosis of dengue is not specific 
and requires an additional effort to confirm probably cases 
in the laboratory. The problem of diagnosis becomes more 
complex, taking into account that many DENV infections are 
asymptomatic –although they may transmit the virus— and 
another large percentage of the infections present with a very 
light febrile presentation, such that often it does not require 
a medical consultation (11). In this document, we review the 
foundations of the laboratory tests that are recommended 
for confirming dengue cases, and we alert readers of the 
difficulties to dengue infection diagnosis confirmation, 
putting forward the need to reinforce the criteria of the 
diagnostic algorithm proposed. This can be useful both for the 
professionals that attend to the patients and for the national 
system of epidemiological surveillance. 
Keys for laboratory diagnosis
Behavior of the virus and immune response during 
infection
The mosquito vector — in Colombia, the species Aedes 
aegypti– upon feeding on the blood of an infected person, 
initiates the replication of the virus in its gastrointestinal 
system and salivary glands. When the mosquito bites a second 
person, it inoculates them with the virus that is present in its 
saliva and initiates the phase that is intrinsic of the replication 
of the virus in human beings. If the person comes in contact 
with the virus for the first time, it is called a primary infection. 
DENV is captured by Langerhans cells in the skin and is 
transported to the lymph nodes where it replicates and infects 
mainly the monocytes that, in turn, head toward the peripheral 
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blood, producing more and more virus. This is called the 
viremic phase (12).
3 to 5 days after the mosquito bite, symptoms begin to 
appear. The day that fever starts is considered day 1 of the 
disease. The febrile phase may last from 3 to 7 days. The 
virus can be detected in the blood during viremia from before 
the temperature increase and in the first days of the fever 
(between days -3 and 3). During the viremic phase, DENV 
can be detected in 30% to 60% of attempts by amplifying the 
viral RNA in the blood serum (13, 17). However, the non-
structural viral protein NS1 can be detected with an ELISA 
assay in approximately 60-80% of the tests even up to 3 or 4 
days after the viremic phase since the viral protein is secreted 
into plasma during viremia and remains detectable even after 
the point in which the virus cannot be isolated (15,16). 
In the acute period of the infection, the levels of IgM 
antibodies are undetectable in 50% of the patients. When the 
fever begins to abate, a period known as defervescence, in 
which the clinical presentation tends to solve itself, the viremia 
disappears, and the IgM titers increase in such a way that 93% 
of the patients at the sixth day are already positive and, after day 
10, all patients have detectable levels of IgM antibodies (17). It 
is for this reason that the IgM antibody detection performed on 
two samples from the patient with an interval of 7 to 14 days 
(acute/convalescent) in which a four-fold increase in the titer 
can be seen in the second compared to the first is considered 
the definitive test for confirming a case (14). 
It is important to highlight that the DENV-specific IgM 
antibody level remain high for 3 months. As such, their 
mere presence is not sufficient for confirming the diagnosis 
of dengue during a febrile presentation. The most frequent 
case of error is an infection by bacterias, parasites, or other 
viruses that causes a febrile presentation similar to that of 
dengue. Thus, if the patient had a dengue infection in the last 
3 months, the IgM serology would be positive. However, it 
would be unrelated to the current presentation, constituting 
a classic false positive. Two to three weeks after the clinical 
presentation, an IgG-specific antibody response is generated, 
antibodies that can be detected by an ELISA test. 
In reality, 4 different types of DENV exist (DENV-1 to 
DENV-4) that can infect a single patient at different times, 
since infection by one does not protect against infection by 
another serotype. In other words, a person in a hyperendemic 
area could suffer from up to 4 different dengue presentations 
over his lifetime. Worse still, it is know that having memory 
antibodies for one of the serotypes is a risk factor for developing 
severe dengue since, during an infection by a serotype that is 
different from that of the first infection, the virus-antibody 
complexes that are formed facilitate the infection of new 
mononuclear cells. The monocytes infected become the targets 
of the immune mechanisms and, upon being attacked, liberate 
chemical mediators that increase capillary permeability, activate 
the complement, secrete cytokines and chemokins, which 
together provoke physiopathological changes that are typical 
of severe dengue (18). 
Later infection by a serotype different than the one that 
caused the primary infection is called secondary infection. 
It leads to a different immune response that affects the 
diagnostic strategy. The clinical presentation is similar to 
that of a primary infection, but the kinetics of the markers 
in the serum are different. The titer of the IgG antibodies 
rises rapidly, while the titer of the IgM antibodies increases, 
but not as much as in a primary infection (Figure 1). As 
occurs during a primary infection, in the acute phase of a 
secondary infection, the virus can be detected in the blood, 
either by amplification of the RNA or by the detection of the 











Figure 1. Visualization of the behavior of biological markers during DENV infection. 
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The viruses of the genus Flavivirus –including the Yellow 
Fever virus, the West Nile virus, the Japanese encephalitis 
virus, the Saint Louis encephalitis virus, etc.—, in their 
protein envelope, have similar sequences that can induce cross 
reactivity in the antibodies. This characteristic represents an 
additional problem for the serological studies of dengue. The 
serums that are positive for yellow fever or, even, the serums 
of individuals vaccinated with the live attenuated virus, 
generate an antibody response that is shared with dengue and 
that may turn out positive in tests in more than 40% of cases. 
This implies a further problem when evaluating serological 
tests for dengue (20). 
Viremia can be detected, thanks to the viral antigen or the 
viral RNA, even before the appearance of fever and during 
the first days. The IgM antibodies in primary infections can 
remain at elevated levels for up to three months after the febrile 
presentation. In secondary infections, the IgG antibodies 
have greater affinity and are more easily detected than the 
IgM antibodies. 
What are the diagnostic tests for dengue? 
The laboratory diagnostic strategy for dengue infections 
is similar to the one used in other viral infections. In the 
case of dengue, it can be confirmed by the detection of the 
virus in the serum, either by detecting the soluble antigen 
(NS1), detecting viral RNA, or by isolating the virus in cell 
cultures (virological methods). A case can also be confirmed 
by evaluating the existence of a specific immunological 
response (serological methods), involving the apparition and 
detection of IgM antibodies in the acute phase, IgG antibodies 
in the convalescent phase, and neutralizing and/or inhibiting 
antibodies in hemagglutination (21). 
Virological methods
ELISA for NS1 detection
The nonstructural protein 1 (NS1) is a glycoprotein that is 
expressed in cells infected by DENV, either anchored to the 
membrane (mNS1) or freed into the extracellular medium in its 
soluble form (sNS1) (22). Based on this principle, an ELISA 
antigen-capture assay was implemented. This consists of an 
ELISA plate that has a monoclonal anti-NS1 antibody attached 
to it. The patient’s serum is placed on this plate, and, if it 
contains the NS1 protein, it will be recognized. After washing, 
it is incubated with an anti-NS1 polyclonal rabbit antibody 
followed by a secondary antibody coupled to the peroxidase 
enzyme that is responsible for generating color upon coming 
in contact with the substrate (hydrogen peroxide) (23). This 
ELISA antigen-capture assay can detect the viral antigen long 
before the IgM appears, and, if there is a positive result in a 
febrile individual, it can confirm the case of dengue. 
Recently, in a previous study, the research team responsible 
for the present document demonstrated that 40% of serums 
coming from probably cases of dengue that were negative 
for IgM were positive for NS1. This confirms them as true 
positives, which makes us question the predictive value of IgM 
in a single serum sample (24). It is also probable that NS1 
cannot be detected in samples taken from patients in days 5 to 
7 after the beginning of the fever. As a result, in these cases, 
additional tests are required for confirmation. The detection 
of NS1 becomes complicated in secondary infections due to 
the fact that the antigen can form specific antibody complexes, 
which makes the capture assay difficult. 
Rapid immunochromatographic NS1 test
The rapid test cassettes for the viral antigen are used more 
and more frequently. It allows health personnel to identify 
the presence of the NS1 viral protein in serum samples from 
febrile patients as part of the initial diagnosis in the point-
of-care. The test is based on the same principle: if the viral 
antigen is present in the serum, it is recognized by a reactant 
of the system, an anti-NS1 antibody coupled with colloidal 
gold. This complex flows thanks to the buffer until finding and 
reacting with a second polyclonal anti-NS1 antibody that traps 
it on the test line, which can be visually perceived as a pink 
or purple line after a few minutes (Figure 2). The importance 
of this test is the possibility that it provides of detecting the 
presence of the virus in the serum (its soluble antigen) while 
the patient is febrile and at a point in which the increase in 
the titer of IgM antibodies is still undetectable. .
In a simultaneous evaluation of several NS1 detection 
systems in Colombian patients, it was found that the ELISA 
assay had a sensitivity of approximately 70%, while the rapid 
immunochromatography tests had a sensitivity of between 
50% and 80%. In this evaluation SD Bioline Dengue Duo Test 
cassettes —which detects NS1, IgM and IgG— showed the 
best behavior with a sensitivity of 80,7% (25). It is important to 
emphasize that rapid tests are subject to the same interpretation 
as the rest of the serological tests, taking into account the day 
of the disease when the sample was taken from the patient, 
how it was handled, and complementary tests. The NS1 test 
may be negative if the sample is taken late during the febrile 
presentation. As such, the combination of various tests and 
formats is suggested for the confirmation of a case. In several 
reports it has been found that sensitivity is greater in primary 
infections than in secondary infections. This may be due to the 
presence of antibodies that form a complex with the NS1 protein, 
thereby avoiding its detection during secondary infections (26).



























Figure 2. Diagram of virological tests used in the dengue cases diagnosis. Note: A. ELISA for the detection of the NS1 antigen from DENV 
in patient serum. The plate is covered with anti-NS1 monoclonal antibodies that, after incubation with the patient serum, capture the 
any viral NS1 protein that is present (I). Later (II), a second anti-NS1 antibody biotin conjugated, followed by the streptavidin complex 
coupled to peroxidase (III). This, with the presence of a substrate and a chromogen for this enzyme (IV), produces a color change that is 
read in the spectrophotometer.  B. Diagram of the basis of a immunochromatographic test (cassette) for NS1 antigen detection in patient 
serum. If the serum contains the viral protein, the monoclonal anti-NS1 antibody that is marked with colloidal gold captures it. This 
complex migrates until reaching a line with anti-NS1 antibodies that, upon reacting, produce the appearance of the positive indicator 
line. C. Appearance of a rapid NS1 detection test in which the two lines are shown (positivity to NS1 and test control). D. Viral isolation 
and Immunofluorescence Assay. The patients’ sera are inoculated on C6/36 mosquito cells and, after several days, the cells are fixed 
and submitted to a process of immunofluorescence to detect the virus (white arrows). E. Detection of viral RNA in patient serum. After 
extraction the RNA from the serum, the viral genome is detected using a reverse transcription technique followed by amplification with 
a polymerase chain reaction (RT-PCR), using specific primers for the four DENV serotypes. 
Detection of viral RNA en serum
For the molecular detection of DENV, a great variety of 
technical protocols have been designed based on blood, serum, 
plasma, or tissue samples with previous complementary DNA 
synthesis for a reverse transcription reaction (RT). The most 
frequently used protocol is that described by Lanciotti et al. 
(1992) and later modified by Chien et al. (2006). It consists of 
a nested RT-PCR, meaning that an amplification of a 511 pb 
fragment is performed using a pair of primers that recognize all 
of the DENV serotypes. Later, a re-amplification is done using 
this product and specific primers for each of the serotypes as a 
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template. Each of the serotypes end in different sized amplicons 
(27,28). Due to its simplicity and ease, the RT-PCR for DENV 
has become the preferred method of many laboratories, since 
its sensitivity is much greater than that of viral isolation. 
DENV diagnosis through molecular biology is more sensitive 
and specific. Although it is possible that false amplifications may 
occur (29), most specialized laboratories have the experience, 
the knowledge, and the equipment necessary for performing 
RT-PCR for DENV. Recently, real-time PCR techniques have 
been introduced that improve the sensitivity and specificity of 
molecular detection. They are also used for research into the 
pathogenesis of disease (30) and have been used to evaluate the 
viral burden of patients (31,32). The assay is based on the use 
of specific pairs of primers and a probe marked with fluorescent 
dye. The regions of viral cDNA, previously synthesized from 
RNA extracted from the sample, are amplified through a classic 
Taq polymerase reaction. The specific probes for each serotype 
are marked with a molecule that produces a different color. They 
hybridize with the cDNA region when they amplify. These 
probes are hydrolyzed causing a change in fluorescence that 
is detected by the equipment and allows the reporting of the 
presence of the virus in the respective sample (33). Although it 
is a method that is costly and requires a high degree of expertise, 
each day it is becomes more sensitive and rapid and less costly. 
As such, it is used more and more frequently.  
Viral isolation and immunofluorescence
In this test, also known as viral culture, a dilution of patient 
serum taken during the acute phase is inoculated into a of 
mosquito cells culture. IF the sample is taken during viremia, 
the virus present in the serum or plasma infects the cells and 
is replicated (34). The test is also done with tissue samples in 
fatal cases (35). Due to the low levels of the virus in the blood, 
to isolate the virus, the sample must be taken early, between 
days 1 and 5 from the initiation of fever. Even in these cases, 
the success rate is 50% as a maximum, though it rarely is more 
than 20% to 30% (36). In general, it is a technique that requires 
specialized installations and personnel, that has high costs, and 
that provides results only 2 weeks after the initiation of the test. 
Thus, it is not very useful for the diagnosis and treatment of 
the patient. Although several types of primate cells are used 
for the isolation, (VERO, LLC-MK2), they are not the best for 
this process. In general, in dengue laboratories, patient serum is 
inoculated into C6/36 or AP-61 mosquito cells from the species 
Aedes albopictus and Aedes pseudoscutellaris respectively 
are used. After several days, cytopathic effects (as syncitya) 
are detected. An additional confirmation is always done using 
antibodies specific to each serotype (ATCC HB-46 to HB49) 
or PCR from the cell lysates (35).
Serological tests
Serology for IgM
This is the primary and most frequently used methodology 
for diagnosis. This test (M antibody capture, MAC-ELISA) 
consists in an ELISA test to which an anti-IgM antibody is 
attached that will recognize immunoglobulin M when the 
problem serum is added. After incubation with a mix of 
antigens from the four DENV serotypes followed by the 
addition of a monoclonal anti-DENV antibody attached to 
an enzyme (phosphatase), it is incubated with the substrate 
that generates the signal (37) (Figure 3). Due to its relatively 
low cost, it is very useful both for surveillance and the study 
of epidemics. However, it does not work for identifying the 
DENV serotypes. If the evaluation is done in paired samples 
—obtained in the acute and convalescent phases— it can be an 
ideal diagnostic method. The sensitivity of the most frequently 
used tests is around 98% when previously confirmed 
dengue samples are used, and under these same conditions, 
the specificity is 90% on average (38). However, in field 
conditions, the probability that MAC-ELISA detects a case of 
dengue from a variety of febrile infections is approximately 
60%, or less if the test is done in the first days of the fever 
(39). As noted above, we must insist on the difficulties of 
serological diagnosis due to the cross-reactivity that occurs 
















Dengue disease diagnosis: 617-629622 





















Reduction of plaques 
with patient serum
Lysis plaques from 
DENV-2 on BHK-21 
Control line
Figure 3. Different serological tests for evaluating specific antibodies for DENV in patients. Notes: A. The IgM antibody capture ELISA test 
(MAC-ELISA). The system has an anti-IgM antibody fixed to the bottom of the plastic plate (I) that, upon contact with the patient serum 
recognizes the IgM pentamere. Later (II), a mix of antigens from the four DENV serotypes is added. The next step (III) is to add a second 
anti-DENV biotin conjugated antibody that reacts by joining the streptavidin complex linked to the phosphatase enzyme (IV). The later 
react with the substrate methylumbelliferyl phosphate (from the Tecnosuma system) that, upon being hydrolyzed by the phosphatase, 
produces fluorescence that is captured and quantified by the fluorometer. This same principle is used for the ELISA format for IgG capture, 
in this case using an anti-IgG attached to the bottom of the plate. B. Detection of IgG antibodies as evidence of a past infection. In this 
case, the plastic plate is covered with fragment of the 4 DENV serotypes. If the patient’s serum has IgG antibodies, they will react with 
the viral antigens, and this complex is recognized with an anti-IgG antibody linked to biotin that, with the addition of streptavidin linked 
to an enzyme, shows the existence of the antibodies upon contact with the substrate. C. Diagram of an immunochromatography system 
(rapid test) for the detection of specific dengue antibodies. If the serum sample contains anti-DENV antibodies (IgM and/or IgG), they react 
with viral proteins that are linked to colloidal gold. They flow by capillarity until reaching anti-IgM or anti-IgG antibodies that stop the 
immunoglobulins of the sample, forming a visible line. D. Appearance of a cassette for IgM or IgG detection in which positivity lines for 
both types of antibodies can be observed.  E. The plaque reduction neutralization test (PRNT) detects antibodies that inhibit infection. If a 
virus suspension is incubated with the serum of a person that has or has had dengue, these antibodies impede the virus from infecting 
the cells in the culture. This is shown by a smaller number of plaques formed by the virus (white spaces on the blue cell monolayer). 
Serology for IgG
For the detection of type-G immunoglobulins (pertaining to 
memory), two formats can be used. The first is the IgG indirect 
ELISA that uses a plate with DENV antigens attached onto 
which the problem serum is added followed by a monoclonal 
human anti-IgG linked to an enzyme. With the substrate, 
this generates a color change (increase in absorbancy). This 
system of indirect antibody detection is useful in studies of 
seroprevalence, no matter the time that has transcurred since 
the infection or the concentration of antibodies. That said, a 
different proposal is put forward in a second format: the IgG 
capture ELISA (40).  In this case, a rabbit anti-human IgG 
antibody is adsorbed to the plate captures all serum IgG, and 
those that are specific to DENV recognize the mix of viral 
antigens that are added later. The next step consists of adding 
a monoclonal anti-DENV antibody linked to peroxidase that, 
upon contact with the substrate and the chromogen, causes 
a color change. This assay is based on the characteristics of 
secondary infections, where the response of IgM antibodies 
is slow, weak, and of a shorter duration than in primary 
infections; some times it is even undetectable. However, one 
or two days after the initiation of the symptoms, the IgGs rise 
rapidly to levels even higher than in the primary infection and 
remain at that point for more than a month. These antibodies 
have greater affinity, thus the cut-off point in the system is 
higher, allowing for a more specific diagnosis. A positive 
result confirms a current or recent presentation of secondary 
dengue. This improves the laboratory confirmation process. 
Hemagglutination Inhibition Assay (HI)
The proteins from the surface of DENV have the capacity 
to agglutinate the erythrocytes of birds (of geese in particular) 
a reaction that can be observed with the naked eye. 
The hemagglutination inhibition assay (HI) consists of 
mixing serial dilutions of patient serum with DENV antigens, 
and later putting the mix in contact with goose erythrocytes. 
If the patient has anti-DENV antibodies, they will attach to 
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the viral proteins, impeding hemagglutination. The result is 
reported as the last dilution of serum that inhibits the HA. A 
titer of more than 1:2650 means that the concentration of anti-
DENV antibodies is very high. This, in turn, means that the 
infection is in course or very recent. However, three months 
after an infection, the titer of hemagglutinating antibodies 
falls. Thus an HI assay will give results below 1:640 (41).
Although this method has been used for a long time and has 
great sensitivity and specificity, it is time consuming and costly 
to perform. It requires a previous manipulation of the serums 
(to eliminate hemagglutinating agents), several dilutions of the 
serum must be made, and it requires the production of purified 
DENV antigens with different concentration and quality. For 
these reasons, this test is used with less and less frequency.
As such, several laboratories have replaced the HI assay 
with the IgG capture ELISA in order to assess the increase 
in titers or to differentiate between primary and secondary 
dengue (42). That said, recently the monoclonal antibody 
based inhibition ELISA has been used. It is just as sensitive 
as the HI assay and has shown its usefulness in the laboratory 
(43).
Immunochromatographic tests (rapid tests cassettes for 
IgM and IgG antibodies)
The rapid  tes ts  for  dengue —lateral - f lowing 
immunochromatography—, has been developed with the goal 
of aiding in the diagnosis in sites where patients are attended. 
The principle is similar to that which was explained for the 
rapid NS1 test. In the IgM or IgG antibody detection cassettes, 
the system contains antigens of the 4 DENV serotypes linked 
to nanoparticles of colloidal gold and, as a control, rabbit IgG 
gold coupled. 
The anti-DENV antibodies in the problem serum recognize 
the gold coupled DENV antigens and migrate along the 
nitrocellulose paper until it reaches a band to which anti-
IgG or anti-IgM antibodies are attached. This band traps 
the respective antibodies that are flowing that, since they 
are attached to the viral antigen linked to the colloidal gold 
nanoparticles, can be seen with the naked eye as a pink or 
purple line (44). The control, a rabbit IgG linked to gold, 
continues to flow until finding its anti-antibody and stops to 
show the positive control line that indicates that the procedure 
was correct. In this way, a qualitative result can be found in 
less than 20 minutes regarding the presence of IgM or IgG in 
the patient’s serum. For example, in a study with 350 serums, 
the different rapid tests for IgM antibodies had a sensitivity 
of between 20% and 95%, with specificities of between 80% 
and 90%. A 40% of false positives presented in the serums 
of patients with malaria and cross-reactions with serums that 
were IgG positive for dengue (38). 
Plaque reduction neutralization test
This assay is the most specific of the serological methods 
and has been used when high specificity detection of anti-
dengue antibodies in a sample from the convalescent phase 
is required. 
The PRNT is a functional assay theat measures the relative 
quantity of antibodies with the capacity of neutralizing 
the infection and reducing the number of infecting viral 
particles, thereby reducing the number of lytic plaques in a 
cell monolayer. With this method, it is possible to specifically 
quantify the titer of neutralizing antibodies for each of the 4 
serotypes of DENV in the individual serum (45). 
The test is based on incubating serial dilutions of the 
patient’s serum with a defined suspension of each of the DENV 
serotypes. In this way, the antibodies attach to the virus that 
later places itself on a cellular monolayer. If the virus is free 
(there are no antibodies), it infects the cells and produces 
plaques in the cell layer (holes) that can be easily counted. 
The number of plaques reduces as the concentration of the 
antibody increases (less dilution of the serum). The result is 
expressed as the dilution of serum that reduces 50% of the 
number of plaques. The great advantage of this method is that 
it can detect with which serotypes of the virus the individual 
has had contact, showing the specific “infection history”. It 
is the method used to quantify the protection in individuals 
immunized with vaccines that are being tried currently and, 
in addition, it is very helpful in seroepidemiology and in 
studies related to the immunopathogenesis of severe dengue 
(46). Despite its great robustness as a diagnostic method, it is 
a technique that is difficult to develop, having high costs and 
requiring great expertise and elements like viruses and cells 
that are all critical for obtaining correct and comparable results. 
Due to the difficulties associated with this technique, 
recently a method was developed that uses the Raji 
lymphoblast cell line that is infected with fluorescent viruses. 
In this way, the reduction in the number of cells infected when 
each viral serotype is treated with dilutions of patient serum 
can be seen through flow cytometry. This technique, though 
costly, allows for the assessment of antecedents of infection 
of a great number of samples (47). 
In Table 1, a summary of the different diagnostic tests and 
their meaning is shown.
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Table 1. Criteria for the diagnosis of dengue in the laboratory
Sample Test Principle Interpretation





The NS1 viral antigen present in the serum attaches to marked 
complexes. The immunocomplex is captured by an immobilized anti-
NS1 agent, creating a visible line. 
Marker of active acute infection. 
Serum NS1 ELISA*
Detection of the viral NS1 antigen in the sample using a plate 
covered with anti-NS1 agent. 
Marker of active acute infection
Serum, plasma, tissues Detection of viral RNA Amplification of the DENV RNA using specific primers Marker of active acute infection
Serum, plasma, tissues Viral isolation Inoculation of the sample serum into mosquito cells C6/36. 
Acute active infection. Not useful for timely 
diagnosis and patient treatment.





The IgM and IgG antibodies of the patient capture coupled antigens, 
making a visible pink line appear. 
Can be used for the presumptive 
differentiation between primary and secondary 
infection. 
Serum IgM capture ELISA
Detection of IgM antibodies through the use of a plate with anti-
IgM antibodies adhered to it. Uses DENV antigens after second 
incubation. 
Positive (mono-serum): recent positive 
infection 
Serum IgG indirect ELISA
Detection of IgG antibodies through the use of a plate with DENV 
antigens attached. An anti-IgG antibody liked to an enzyme that, 
with the addition of the substrate produces a color change. 
Positive: evidence of past or recent dengue 
infection. 
Serum IgG capture ELISA
The IgG antibodies present in the serum react with the anti-IgG 
antibodies present in the plate. Uses DENV antigens in second 
incubation.  
Positive: secondary infection from dengue, or 
evidence of recent exposure. 
Serum,  plasma Hemagglutination inhibition †
The DENV antibodies present in the sample attach to the DENV 
proteins, impeding them from coming into contact with goose 
erythrocytes and hemagglutination. 
Permits differentiation between primary 
infections and secondary infection, depending 




Dilutions of serum come into contact with a suspension of DENV 
serotypes, and this is inoculated into a cell monolayer. The number 
of plaques diminishes if the patient had come in contact with the 
viral serotype in question. 
Specific identification of the serotype(s) 
responsible for the past infection(s) in the 
patient. 
Notes: * Should be used together with other diagnostic tests. † Performed in the convalescent phase. 
The puzzle of dengue diagnosis
The early identification of dengue infection is a key element 
in providing timely care for its complications that usually 
occur around the 5th day of the disease (48). Therefore, delays 
in the diagnosis can affect the prognosis, since the inadequate 
management of these patients in early days (due to a poor 
diagnosis) could lead to late detection and serious or even 
fatal complications. 
One of the main problems with the management of dengue in 
endemic zones is the difficulty associated with distinguishing it 
in a timely fashion from other infections with a similar febrile 
presentation, such as influenza, diarrheal diseases, measles, 
typhoid fever, malaria, yellow fever, and leptospirosis to name 
a few (49,50). Surveillance and diagnosis of dengue using 
only clinical criteria have a very low sensitivity and should 
be accompanied by a laboratory diagnostic process both of the 
health institution and of specialized laboratories (Colombian 
regional laboratories and the National Health Institute). In 
this review, each of the recommended tests for confirming 
a case of dengue in the laboratory have been described. As 
can be seen, some of these tests require trained personnel, 
specialized equipment, and special resources. The timely 
taking and appropriate handling of the clinical samples is 
also important, something that ensures higher sensitivity and 
specificity in the tests. As described earlier, the confirmation 
of the dengue cases presents many difficulties that should be 
strictly evaluated to ensure the attainment of a result (51). 
These difficulties are related to the fact that there are 4 
serotypes of DENV that can infect a patient at any point in 
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time. It is well known that the antibodies of one serotype are 
only weakly effective against other serotypes. In fact, they 
function as opsonizing antibodies that increase the proportion 
of infected cells and as a result, the cytokine response. In the 
same way, diagnosis is made difficult by the cross-reaction 
that the anti-DENV antibodies have against other flaviviruses, 
such as the yellow fever virus and even the vaccine virus. The 
short viremia period also makes detection of the antigen or 
of viral RNA difficult in the acute phase. The most sensitive 
and specific test is assessment through the ELISA or the HI 
seroconversion or increase antibody titer tests, but it requires 
the analysis of two samples taken with an interval greater 
than 7 days (acute vs. convalescent). Lastly, the long-term 
persistence of memory antibodies may falsify the tests during 
acute infections. 
Considering this panorama and the interest in confirming 
the cases in the laboratory, we have proposed various elements 
that may improve diagnoses. Operatively, a “probable case” 
is defined as an acute febrile episode with dengue symptoms 
(warning signs may appear) or severe cases with evidence of 
plasma leakage, severe hemorrhages, and/or damage in other 
organs (7). A “confirmed case” would be a probable case that 
has additional positive serological or virological evidence. 
A  positive result can be established if the viral protein 
NS1 is found (through the ELISA or immunochromatography 
test) or by amplifying the viral RNA through RT-PCR. This 
is possible in patients with less than 5 days of evolution, 
although the shorter the time since the initiation of the fever, 
the greater the probability of detection. The most specific 
test, the less sensitive, is the “viral isolation” test, however, 
it requires inoculating the patient’s serum into cell cultures 
and later confirming the diagnosis through fluorescence with 
monoclonal antibodies or by RT-PCR amplification. Due to 
the low sensitivity of these three techniques, a negative result 
does not rule out the dengue diagnosis. Therefore, whenever 
possible, it is recommended that at least two of the tests should 
be run simultaneously. 
The gold standard test in the diagnosis is considered to 
the be the capture ELISA for the detection of IgM or IgG 
antibodies in two samples from the same patient taken with 
an interval of at least seven days. This test, however, may not 
be very useful for the patient. In this case, it can be shown 
that the serum from the acute phase is negative (or with a low 
absorbence signal) and that the sample from the convalescent 
phase shows the signal (seroconversion) or the signal increases 
significantly. In the great majority of the cases, only one sample 
of the patient is available (single serum) taken during the acute 
phase. If this single sample is positive for anti-dengue IgM 
or IgG capture, the case is considered “undetermined” unless 
a RT-PCR or NS1 detection test is done. Unfortunately, this 
is the most frequent state of definition of cases in Colombia. 
Frequently, in dengue endemic zones, there are patients that 
consult due to a febrile syndrome that is compatible with the 
symptoms of dengue and present a positive IgM serology. 
It is impossible with this single test to know if the febrile 
case is due to DENV, since the positive serology of a single 
serum could be due to a presentation of dengue that occurred 
in the last three months. This interpretation is valid both for 
the cases studied through IgM serology and for the rapid 
immunochromatographic test for IgM detection. 
In cases of deceased patients who had a dengue compatible 
clinical presentation, the detection of the viral antigen by 
immunohistochemistry or the amplification of the viral RNA 
is recommended in samples of tissue fragments obtained 
from autopsies. Finally, the laboratory diagnostic must be 
complementary to a clinical evaluation that systematically 
investigates the disease through the signs and symptoms, as 
proposed by Díaz-Quijano et al. (2006). In their study, a score 
was assigned to each sign or symptom, noticeably improving 
the sensitivity and specificity of the process (42.4% and 
96%, respectively) (8). In this way, a better clinical approach 
also favors laboratory confirmation, provides the benefit 
of immediate attention to the patient, and strengthens the 
institutional surveillance because can be avoided the variation 
dependent on the cases definition or the day when the samples 
were taken. 
It is expected that the expression of recombinant viral 
proteins could improve the specificity of the new systems 
by avoiding the epitopes shared by flaviviruses. Due to the 
great variability of the sensitivity and specificity values that 
are reported in the publications, a call has been made to the 
researches to evaluate the existing diagnostic systems in 
multi-center field tests. In view of the fact that serious cases 
are on the rise, we also suggest that the circulating serotypes 
be identified along with primary cases versus secondary cases, 
since this will positively affect epidemiological surveillance. 
Unfortunately, in order to evaluate the current diagnostic 
systems, reactants are needed (viruses, antigens), as well as 
standardized positive and negative serums, that can be used 
for the standardization of the country’s diagnostic laboratories. 
This, without counting the difficulties associated with the 
more complex tests, like molecular detection and typification 
through RT-PCR or viral isolation in cell cultures, tests which 
should be standardized in more laboratories in order to widen 
the coverage of specific diagnoses. 
The research groups and the companies that produce 
diagnostic kits are moving toward the development of 
more sensitive and specific systems. Nevertheless, it is 
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also important that they have a lower cost, allowing health 
institutions in endemic zones to have access to the products, 
and to be able to further the tests and support the diagnosis 
of the cases. The new systems have the challenge of aiming 
toward earlier diagnosis of the individuals and eliminating 
interference from the response of other flaviviruses. New 
systems must be able to make a serological diagnosis of the 
infecting serotype and allow for genomic studies of the viruses 
or even the assessment of the viral burden. It also is proposed 
that new systems should be able to work with different kinds 
of samples (plasma, saliva, urine, etc.) 
In addition, tests for the assessment of biomarkers are in 
development. These tests could be associated with a better 
prognosis and aftercare. Interested laboratories should start to 
share information, reactants, antibodies, positive and negative 
control serums, viral isolates, and cell cultures in order to 
standardize robust and appropriate processes for the existing 
diagnostic kits, and for those of the future (52). 
Conclusions
Despite the advances in most recent years in immunological, 
virological, molecular, and cellular techniques, objective 
difficulties still exist with regard to the confirmation of dengue 
cases. Operative problems range from, for example, the 
appropriate time to take a sample, to its handling and transport 
to the laboratory, to the tests to be performed depending on the 
laboratory’s level of expertise and the time required for the results 
to be ready. Furthermore, the difficulty of a highly specific clinical 
diagnosis, and the little experience of first and second level 
laboratories with the topic, should be dealt with so as to create 
new spaces where the task of integral diagnosis can be performed. 
The IgM capture ELISA should become a routine technique 
in all hospitals and clinics, taking advantage of the fact that it 
is included among the benefits of the health insurance system. 
The use of rapid tests in care centers (since they have not shown 
greater sensitivity than the ELISA test) should be accompanied 
by correct training of the personnel for the identification of the 
signs and symptoms of a mild clinical presentation and warning 
signs. With increased incidence, an effort should be made to 
collect and process samples with serological and virological 
techniques in specialized laboratories in order to verify the real 
magnitude of the disease in the country and contribute to its 
control. As can be seen here, this is an effort that includes all 
actors of the general health system, and tasks should be set out 
that lead us to better dengue diagnoses.
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